PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514918
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514918
Prosthetic Joint Infection Treatment Market size was valued at USD 188.78 Million in 2023, expanding at a CAGR of 4.6% from 2024 to 2032.
Treatment for prosthetic joint infections (PJIs) focuses on controlling infections in artificial joints, like knee or hip replacements. Because of the formation of biofilms, antibiotic resistance, and the possibility of severe consequences from untreated infections, these infections can be difficult to treat. Depending on the specific needs of each patient, treatment plans often combine medicinal and surgical procedures.
Prosthetic Joint Infection Treatment Market- Market Dynamics
The rising prevalence of joint replacement surgeries and the development of diagnostic techniques are expected to propel market demand
There is an increasing need for joint replacement surgery, such as hip and knee replacements, as the world's population ages and leads different lifestyles which is boosting the market growth. Effective treatment solutions are in high demand as the number of surgeries performed is rising along with the prevalence of prosthetic joint infections. Prosthetic joint infections are not an exception to the worldwide trend of antibiotic resistance. The advent of bacterial strains resistant to antibiotics affects the management of pressure injuries (PJIs) and calls for the creation of novel treatments and treatment approaches.
Prosthetic joint infections can now be detected more quickly and accurately thanks to advancements in diagnostic methods including molecular diagnostic tools and sophisticated imaging modalities. The need for related treatment choices might be influenced by early detection, which is essential for effective therapy. There are now more alternatives for treating prosthetic joint infections thanks to the introduction of newer therapeutic methods such as biofilm-targeting drugs, antibiotic-loaded bone cement, and sophisticated surgical techniques. These developments have the potential to boost market expansion, lower recurrence rates, and enhance treatment outcomes. Together, these factors support the expansion and growth of the prosthetic joint infection treatment industry.
Prosthetic Joint Infection Treatment Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.6% over the forecast period (2024-2032)
Based on Type segmentation, the fusidic acid segment was predicted to show maximum market share in the year 2023, owing to its high effectiveness in PJI treatment.
Based on Application segmentation, the clinical segment was the leading Application in 2023, due to high demand in clinical operations.
Based on End User segmentation, the hospital segment was the leading End User in 2023, owing to the high prevalence of PJI related surgery treatment at hospitals.
Based on region, North America was the leading revenue generator in 2023, owing to growing surgery & high demand for PJI treatment.
The Global Prosthetic Joint Infection Treatment Market is segmented based on Type, Application, End User, and Region.
The market is divided into five categories based on Type: fusidic acid, Lefamulin acetate, MTF-101, TNP-2092, and others. The fusidic acid segment dominates the market. Fusidic acid is highly effective in treating PJI related disorders.
The market is divided into three categories based on the Application: clinical, medical procedures, and others. The clinical segment dominates the market. The growing need for orthopedic practices, and joint replacement surgeries, is fueling market growth.
The market is divided into three categories based on End Users: hospitals, clinics, and others. The hospital segment dominates the market and is expected to maintain its high dominance during the forecast period. High prevalence of joint related surgeries, orthopedic surgery disorders are augmenting the segment growth.
Prosthetic Joint Infection Treatment Market- Geographical Insights
Globally, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is expected to be a significant contributor to the PJI treatment market due to factors such as a high prevalence of joint replacement surgeries, advanced healthcare infrastructure, and a strong focus on medical innovation. The United States, in particular, accounts for a substantial share of the global market. Latin America is emerging as a promising market for PJI treatment, supported by improving healthcare infrastructure.
The Prosthetic Joint Infection Treatment market is made up of small & large market participants. Market players have been investing in research and development to enhance their portfolio of PJI treatment solutions. Recent developments include the introduction of advanced implant materials designed to reduce the risk of infection and improve patient outcomes. Companies also focus on offering a range of products for PJI treatment, including antimicrobial dressings, wound care solutions, and surgical instruments.
In June 2024, Osteal Therapeutics raised USD 50 million in Series D investment, as the orthopedic infection treatment specialist wants to expand their business.
In August 2022, Armata Pharmaceuticals announced approval of its new drug application AP-SA02 in prosthetic joint infection (PJI).